| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | R Julian Preston | Q122981015 |
| P2093 | author name string | Peter M J Bos | |
| Joel P Bercu | |||
| Serrine S Lau | |||
| Rory B Conolly | |||
| Alan R Boobis | |||
| Nancy G Doerrer | |||
| A Robert Schnatter | |||
| P Michael Bolger | |||
| Philip Carthew | |||
| Jay I Goodman | |||
| Rita Schoeny | |||
| Angelika Tritscher | |||
| Gary M Williams | |||
| Susan P Felter | |||
| David J Kirkland | |||
| Frans van Velsen | |||
| G Craig Llewellyn | |||
| Wafa A Harrouk | |||
| P2860 | cites work | Finding the missing heritability of complex diseases | Q22122198 |
| Oncogenes and Cancer | Q22248112 | ||
| Temporal variation in the association between benzene and leukemia mortality | Q23911659 | ||
| Adjustment for temporal confounders in a reanalysis of a case-control study of beryllium and lung cancer | Q23917376 | ||
| Lung cancer case control study of beryllium workers | Q24169597 | ||
| The age distribution of cancer and a multi-stage theory of carcinogenesis | Q24564904 | ||
| DNA mismatch repair: molecular mechanism, cancer, and ageing | Q24647002 | ||
| Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies | Q24653818 | ||
| Mortality and cancer incidence following occupational radiation exposure: third analysis of the National Registry for Radiation Workers | Q24658544 | ||
| Cancer and developmental exposure to endocrine disruptors | Q24814029 | ||
| Assessing susceptibility from early-life exposure to carcinogens | Q24815464 | ||
| An evaluation of the implementation of the Cramer classification scheme in the Toxtree software | Q52227990 | ||
| Carcinogenic risk assessment with time-dependent exposure patterns. | Q52547638 | ||
| Using average lifetime dose rate for intermittent exposures to carcinogens. | Q52589079 | ||
| Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. | Q52604250 | ||
| A new method for determining allowable daily intakes. | Q52687390 | ||
| Comparison of carcinogenic and in vivo genotoxic potency estimates. | Q53361230 | ||
| Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose. | Q53425954 | ||
| Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. | Q53462468 | ||
| Effect of varying exposure regimens on methylene chloride-induced lung and liver tumors in female B6C3F1 mice. | Q53480452 | ||
| Rodent carcinogens: setting priorities | Q53486868 | ||
| Evaluation of the newborn mouse model for chemical tumorigenesis | Q53497195 | ||
| Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. | Q53553612 | ||
| The effect of age and exposure duration on cancer induction by a known carcinogen in rats, mice, and hamsters. | Q53560044 | ||
| Exposure to beryllium and occurrence of lung cancer: a reexamination of findings from a nested case-control study. | Q53581050 | ||
| IPCS framework for analyzing the relevance of a cancer mode of action for humans. | Q53587174 | ||
| Structural motifs modulating the carcinogenic risk of aromatic amines | Q56914927 | ||
| Decrease in risk of lung cancer death in males after smoking cessation by age at quitting: findings from the JACC study | Q45222172 | ||
| Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals I. Alternative toxicity measures as an estimator of carcinogenic potency | Q46111506 | ||
| Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. | Q46827417 | ||
| Evaluating the human relevance of chemically induced animal tumors | Q47250065 | ||
| A tiered approach to threshold of regulation | Q50125469 | ||
| Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay | Q50926494 | ||
| Uncertainty in cancer risk estimates | Q51052651 | ||
| A framework for using structural, reactivity, metabolic and physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological assessments. | Q51791622 | ||
| Use of genotoxicity data to support clinical trials or positive genetox findings on a candidate pharmaceutical or impurity .... now what? | Q51815216 | ||
| Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. | Q52025560 | ||
| Mechanistic basis for nonlinearities and thresholds in rat liver carcinogenesis by the DNA-reactive carcinogens 2-acetylaminofluorene and diethylnitrosamine. | Q52077247 | ||
| Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. | Q52122632 | ||
| Haber's rule: a special case in a family of curves relating concentration and duration of exposure to a fixed level of response for a given endpoint | Q28144801 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review | Q28286389 | ||
| Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk | Q28390064 | ||
| Cancer epigenomics: DNA methylomes and histone-modification maps | Q29615524 | ||
| Solid cancer incidence in atomic bomb survivors: 1958-1998 | Q29620810 | ||
| A carcinogenic potency database of the standardized results of animal bioassays | Q30498518 | ||
| Prediction of cancer potency using a battery of mutation and toxicity data | Q30655184 | ||
| Drug-like properties and the causes of poor solubility and poor permeability | Q30660926 | ||
| Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data | Q31029852 | ||
| Reevaluation of benzene exposure for the Pliofilm (rubberworker) cohort (1936-1976). | Q33227565 | ||
| Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity | Q33445819 | ||
| A comprehensive approach for integration of toxicity and cancer risk assessments | Q33537456 | ||
| A procedure for the safety evaluation of flavouring substances. Joint FAO/WHO Expert Committee on Food Additives | Q33607826 | ||
| Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk | Q33632467 | ||
| The Single Exposure Carcinogen Database: assessing the circumstances under which a single exposure to a carcinogen can cause cancer | Q33729429 | ||
| Application of key events analysis to chemical carcinogens and noncarcinogens | Q33736229 | ||
| What role for biologically based dose-response models in estimating low-dose risk? | Q33837778 | ||
| Carcinogenesis in mouse and human cells: parallels and paradoxes | Q33846175 | ||
| Dose and time as variables of toxicity | Q33899185 | ||
| Development of the murine and human immune system: differential effects of immunotoxicants depend on time of exposure | Q33942473 | ||
| Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models | Q33942505 | ||
| The use of Haber's law in standard setting and risk assessment | Q34017647 | ||
| The role of time in toxicology or Haber's c x t product | Q34017651 | ||
| Cancer genetics. | Q34253580 | ||
| Neonatal mouse model: review of methods and results | Q34429222 | ||
| Altered DNA methylation: a secondary mechanism involved in carcinogenesis | Q34504084 | ||
| Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat | Q34528278 | ||
| Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity | Q34560275 | ||
| The causes and prevention of cancer: gaining perspective | Q34638943 | ||
| Extending the threshold of regulation concept: de minimis limits for carcinogens and mutagens | Q34672935 | ||
| Differential sensitivity of children and adults to chemical toxicity. I. Biological basis | Q34803159 | ||
| The carcinogenesis bioassay in perspective: application in identifying human cancer hazards | Q34864407 | ||
| 13th Meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC): alternative testing methodologies for organ toxicity | Q34942041 | ||
| Differences between children and adults: implications for risk assessment at California EPA. | Q34978971 | ||
| Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. | Q35032604 | ||
| The Carcinogenic Potency Database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program | Q35034775 | ||
| Are genotoxic carcinogens more potent than nongenotoxic carcinogens? | Q35035161 | ||
| Cancer induction following single and multiple exposures to a constant amount of vinyl chloride monomer | Q35036244 | ||
| Lymphohaematopoeitic cancer mortality among workers with benzene exposure | Q35499572 | ||
| Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet | Q35589744 | ||
| Species comparison of anatomical and functional immune system development | Q35604528 | ||
| A framework for human relevance analysis of information on carcinogenic modes of action | Q35631055 | ||
| Risk assessment of peak exposure to genotoxic carcinogens: a pragmatic approach | Q35792379 | ||
| Dose-dependent transitions in mechanisms of toxicity: case studies | Q35975278 | ||
| Trichloroethylene: mechanisms of renal toxicity and renal cancer and relevance to risk assessment | Q36371845 | ||
| Organ and cell specificity of base excision repair mutants in mice | Q36502641 | ||
| Formaldehyde and glutaraldehyde and nasal cytotoxicity: case study within the context of the 2006 IPCS Human Framework for the Analysis of a cancer mode of action for humans | Q36659785 | ||
| Nasal cytotoxic and carcinogenic activities of systemically distributed organic chemicals | Q36688003 | ||
| The cumulative risk of lung cancer among current, ex- and never-smokers in European men. | Q36695716 | ||
| Genome instability and DNA damage accumulation in gene-targeted mice. | Q36705572 | ||
| Mechanistic data and risk assessment of selected toxic end points of the thyroid gland | Q36849669 | ||
| Targeted deletion of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence of novel carcinogenic oxidative damage to DNA. | Q36972337 | ||
| Promotion of hepatocarcinogenesis in humans and animal models | Q37060367 | ||
| The context and potential of epigenetics in oncology | Q37123413 | ||
| Evaluation of potential human carcinogenicity of the synthetic monomer ethyl acrylate | Q37302248 | ||
| Generation, biological consequences and repair mechanisms of cytosine deamination in DNA. | Q37318650 | ||
| Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives | Q37468717 | ||
| Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research | Q37647283 | ||
| Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic: example: aflatoxin B1 (AFB1). | Q37683875 | ||
| Proposed mechanism of induction of gastric carcinoids: the gastrin hypothesis | Q37830513 | ||
| Estimation of toxic hazard—A decision tree approach | Q39771165 | ||
| In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances | Q39886219 | ||
| Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis | Q40595580 | ||
| IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis | Q40681312 | ||
| DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation | Q42279753 | ||
| Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine | Q42284621 | ||
| Carcinogens are mutagens: their detection and classification | Q42414754 | ||
| The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination? | Q43288862 | ||
| Using the Biological Two-Stage Model to Assess Risk from Short-Term Exposures | Q44256571 | ||
| Cancer risk assessment with intermittent exposure | Q44663070 | ||
| N-ethyl-N-nitrosourea (ENU) increased brain mutations in prenatal and neonatal mice but not in the adults. | Q44907968 | ||
| Thresholds for the effects of 2-acetylaminofluorene in rat liver | Q45123174 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | exposure assessment | Q4008388 |
| P304 | page(s) | 507-544 | |
| P577 | publication date | 2011-05-18 | |
| P1433 | published in | Critical Reviews in Toxicology | Q3562267 |
| P1476 | title | A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens | |
| P478 | volume | 41 |
| Q87244539 | A TTC threshold for acute oral exposure to non-genotoxic substances |
| Q47434915 | Active pharmaceutical ingredients detected in herbal food supplements for weight loss sampled on the Dutch market. |
| Q36566677 | Advancing the next generation of health risk assessment |
| Q46866657 | Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance |
| Q47579313 | Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials |
| Q38686742 | County-level cumulative environmental quality associated with cancer incidence |
| Q50481348 | Critical elements for human health risk assessment of less than lifetime exposures |
| Q48360872 | Determination and risk assessment of naturally occurring genotoxic and carcinogenic alkenylbenzenes in nutmeg-based plant food supplements |
| Q53249632 | Establishing the level of safety concern for chemicals in food without the need for toxicity testing. |
| Q97073010 | Guidance on the use of the Threshold of Toxicological Concern approach in food safety assessment |
| Q38020789 | Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes--conclusions from the 3rd International ESTP Expert Workshop |
| Q39662033 | Mechanistic study on lung cancer mortality after radon exposure in the Wismut cohort supports important role of clonal expansion in lung carcinogenesis |
| Q50168354 | Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides |
| Q44173916 | Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities |
| Q48329721 | Risk assessment of combined exposure to alkenylbenzenes through consumption of plant food supplements containing parsley and dill. |
| Q39149237 | Risk assessment of plant food supplements and other herbal products containing aristolochic acids using the margin of exposure (MOE) approach |
| Q28396943 | Risk-based indicators of Canadians' exposures to environmental carcinogens |
Search more.